Psilocybin’s Potential Impact on Bipolar Disorder
Psilocybin, the active compound in “magic mushrooms,” may offer relief from depressive episodes for individuals with bipolar disorder. Interestingly, it appears to do this without triggering mania or mood swings, which can happen with standard antidepressants.
This insight comes from a small clinical trial published recently in JAMA Psychiatry.
The trial involved 15 participants diagnosed with bipolar II, characterized by prolonged depressive states and shorter bursts of “hypomania“, where individuals may experience heightened energy levels. In contrast, bipolar I includes episodes of both depression and mania, which is more intense and can lead to risky behaviors or psychosis.
During the study, participants paused their usual mood medications for at least two weeks before receiving a single dose of synthetic psilocybin. All were dealing with depressive episodes that weren’t responding well to their ongoing treatments. Additionally, they engaged in talk therapy at various stages around the administration of psilocybin.
Three weeks after treatment, all participants reported improvement in depressive symptoms according to a standardized test. Remarkably, twelve of them showed at least a 50% reduction in their scores, indicating significant relief, and 11 participants achieved remission. Most of those who went into remission experienced this swiftly, within just a week following the psilocybin dose.
Looking 12 weeks post-treatment, 12 participants remained in remission, and the test scores for signs of hypomania and mania remained stable, which is notable. This is a crucial point since many common antidepressants, especially selective serotonin reuptake inhibitors, can sometimes evoke manic episodes and contribute to mood instability for those with bipolar disorder.
The study authors noted, “Participants displayed strong and sustained antidepressant effects without any indication of worsened mood instability or increased suicidality.”
These findings emphasize the need for further exploration of psilocybin’s effects in larger populations with bipolar II. However, the authors also warned against applying these results to bipolar I patients, as they might be more susceptible to manic episodes if treated similarly.
This trial marks “an important advancement” in researching psilocybin for bipolar disorder, especially since recent studies have typically excluded participants with relevant personal or familial histories of bipolar conditions. Experts from the Johns Hopkins Center for Psychedelic and Consciousness Research remarked that this exclusion was largely due to concerns that psychedelics might provoke mania.
They found the study’s safety data particularly encouraging, stating, “The favorable safety profile of this study strongly supports larger randomized clinical trials of psilocybin for depression in bipolar II.” However, it’s worth mentioning the trial had its limitations. The small participant group and their generally moderate symptoms were significant factors. Furthermore, the trial lacked a control group receiving a placebo, which makes it difficult to gauge psilocybin’s effectiveness compared to therapy alone.
“Many uncertainties remain, particularly regarding long-term effects and likelihood of relapse,” the researchers added. One participant initially in remission at three weeks later relapsed and was classified as a “nonresponder” at the 12-week mark.
While this trial is a promising initial step, both the organizers and commentators emphasized that extensive further research is essential.
